Asia-Pacific Diagnostic Tests Market Revenue Estimated Around USD 554.01 Billion By 2034

According to the report, the Asia-Pacific diagnostic tests market size was valued at approximately USD 197.41 billion in 2024 and is predicted to reach around USD 554.01 billion by the end of 2034, expanding at a CAGR of around 10.87% from 2025 to 2034. The Asia-Pacific diagnostic tests industry refers to the research, design, production, and distribution of diagnostic tools that are used for several medical purposes. However, the market only deals with issues in the Asia-Pacific region and focuses mainly on countries such as China, Japan, India, Australia, South Korea, and others.

Diagnostic tests are medical tools that are used for the accurate diagnosis of several medical conditions, diseases, or infections in patients. It includes a wide range of equipment, with some devices being more general in terms of diagnosis, while some tools are produced for specific conditions.

The regional market plays a crucial role in the industry due to the ongoing rise in investment directed toward more research, along with a higher potential for further expansion in Asian countries. During the forecast period, the industry may witness high growth but will also face certain restrictions and challenges.

The Asia-Pacific diagnostic tests market is projected to grow owing to the increasing geriatric population in the regions of Japan, China, and other countries. The elderly population is more vulnerable to contracting several conditions, some of which are age-induced and some may be due to previous medical conditions. As per official reports, more than 28% of Japan’s population is over 65 years of age, which directly impacts the country’s healthcare system.

In addition to this, the increasing investment toward developing new and accurate diagnostic tools, especially in the oncology segment, could lead to higher revenue growth. For instance, in 2020, India spent nearly INR 2300 crore on the treatment of oral cancer in the region. In addition to this, the regions of Japan, India, South Korea, and China are investing in drastic technological improvements and focusing on breakthrough diagnostic tests such as molecular diagnostics and point-of-care testing. The increasing prevalence of medical diseases such as cancer and diabetes is another leading cause of the regional market size.

However, the Asia-Pacific diagnostic test industry also deals with several restraints in terms of a lack of awareness and education. A large part of the population, especially in underdeveloped countries, does not have the necessary awareness about the different types of diagnostic tools for specific medical conditions. This part of the patient group solely relies on government drives or initiatives by healthcare agencies. The frequency of such programs may be less as compared to the population strength. Furthermore, the increasing regulatory hurdles against approval and commercial sale of diagnostic tests are another significant barrier that greatly restricts market growth. The growing efforts toward self-dependence could provide growth opportunities, while the large market fragmentation could challenge market growth.

The Asia-Pacific diagnostic tests market is segmented based on test type, application, end-user, technology, and region.

Based on Test Type, the Asia-Pacific diagnostic tests market is divided into blood tests, urine tests, imaging, genetic tests, biopsy, and others. On the basis of Application, the Asia-Pacific diagnostic tests market is bifurcated into infectious diseases, cancer, cardiovascular, diabetes, neurology, and others. By End-user, the Asia-Pacific diagnostic tests market is split into hospitals, clinics, diagnostic laboratories, homecare, and research institutes. In terms of Technology, the Asia-Pacific diagnostic tests market is categorized into PCR, ELISA, rapid test, next-generation sequencing (NGS), and imaging.

Asia-Pacific Diagnostic Tests Market: Report Scope

The Asia-Pacific diagnostic tests market is expected to witness the highest growth in Japan, mainly due to the protective care approach adopted by the regional government to ensure 100% accessibility to quality medical care for its residents. China is expected to emerge as one of the highest contributing nations in the regional market due to the growing emphasis on developing the country’s medical infrastructure.

Some of the largest medical diagnostic tool manufacturers are present in China, which have currently amplified their spending on further research & development. India is witnessing a surge in healthcare expenditure from the government’s side as demand for medical diagnosis and care has increased over the years. The country is focusing on the domestic production of diagnostic tests for several conditions, including cancer and other serious issues.

This review is based on a report by Zion Market Research, titled “Asia-Pacific Diagnostic Tests Market By Test Type (Blood Tests, Urine Tests, Imaging, Genetic Tests, Biopsy, and Others), By Application (Infectious Diseases, Cancer, Cardiovascular, Diabetes, Neurology, and Others), By End-user (Hospitals, Clinics, Diagnostic Laboratories, Homecare, and Research Institutes), By Technology (PCR, ELISA, Rapid Test, Next-Generation Sequencing (NGS), and Imaging), and By Country: Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034”- Report at https://www.zionmarketresearch.com/report/asia-pacific-diagnostic-tests-market

Recent Developments:

• In June 2022, Mylab Discovery Solutions, an Indian healthcare company, announced the last of PregaScreen, which is an at-home pregnancy test kit

• In January 2023, Atomo Diagnostic, an Australia-based healthcare company, signed a partnership with NG Biotech SAS for the production and sale of its pregnancy tests in regions of Canada, the US, and New Zealand

Asia-Pacific Diagnostic Tests Market: Competitive Analysis

The Asia-Pacific diagnostic tests market is dominated by players like:

• Mindray Medical International Limited
• Roche Diagnostics
• Bio-Rad Laboratories
• Abbott Laboratories
• Becton
• Dickinson and Company
• Siemens Healthineers
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation
• QIAGEN N.V.
• Thermo Fisher Scientific
• Beckman Coulter Inc.
• Sysmex Corporation
• Bio-Rad Laboratories
• Hologic Inc.
• Ortho Clinical Diagnostics
• Cepheid Inc.
• Luminex Corporation
• Meridian Bioscience Inc.
• Eiken Chemical Co., Ltd.
• Nihon Kohden Corporation
• Alere Inc.
• BioMérieux SA
• DiaSorin S.p.A.
• Fujirebio Inc.
• and Grifols S.A.

The Asia-Pacific diagnostic tests market is segmented as follows;

By Test Type

• Blood Tests
• Urine Tests
• Imaging
• Genetic Tests
• Biopsy
• Others

By Application

• Infectious Diseases
• Cancer
• Cardiovascular
• Diabetes
• Neurology
• Others

By End-user

• Hospitals
• Clinics
• Diagnostic Laboratories
• Homecare
• Research Institutes

By Technology

• PCR
• ELISA
• Rapid Test
• Next-Generation Sequencing (NGS)
• Imaging

By Region

• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
• Rest of Asia Pacific

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports, to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database has been updated constantly in order to provide our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on industries, products, and market trends in this database. Last but not least, we make it our duty to ensure the success of clients connected to us—after all, if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com